EMD Stock Overview Engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia. More details
Risk Analysis + 1 more risk
See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
Emyria Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Emyria Historical stock prices Current Share Price AU$0.034 52 Week High AU$0.074 52 Week Low AU$0.027 Beta 0.79 1 Month Change 3.03% 3 Month Change -2.86% 1 Year Change -35.85% 3 Year Change -88.47% 5 Year Change -67.62% Change since IPO -76.55%
Recent News & Updates
Less than half of directors are independent Feb 04 Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.525 million. Nov 27
New major risk - Share price stability Nov 14
Emyria Limited, Annual General Meeting, Nov 12, 2024 Oct 11
Full year 2024 earnings released: AU$0.032 loss per share (vs AU$0.018 loss in FY 2023) Aug 31
New minor risk - Share price stability Aug 09 See more updates
Less than half of directors are independent Feb 04 Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.525 million. Nov 27
New major risk - Share price stability Nov 14
Emyria Limited, Annual General Meeting, Nov 12, 2024 Oct 11
Full year 2024 earnings released: AU$0.032 loss per share (vs AU$0.018 loss in FY 2023) Aug 31
New minor risk - Share price stability Aug 09
New major risk - Market cap size Aug 07 Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.3 million. Apr 24
New major risk - Financial position Feb 29
Emyria Limited Appoints Greg Hutchinson as Director Nov 22
Emyria Limited Announces Board Changes Nov 15 Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.678228 million. Nov 11
Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd. Sep 15
Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd. Sep 14
Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022) Sep 01
Emyria Limited, Annual General Meeting, Nov 16, 2023 Aug 31
New minor risk - Financial data availability Aug 29
Emyria Limited Announces Strategic Board Transition Aug 21
New minor risk - Share price stability Aug 04
Emyria Limited (ASX:EMD) signed an agreement to acquire The Pax Centre from Glenroyale Pty Ltd for AUD 1.7 million. Jul 04
Emyria Limited Secures Clinical-Grade MDMA Supply for Aust Patients Feb 13
Emyria Limited Expands MDMA Programs Following Landmark TGA Decision Feb 08
Emyria Limited Announces Commencement of First Dosing for Pivotal EMD-RX5 Phase 3 Trial Jan 30
Emyria Limited Announces Its Acceptance into the Preclinical Screening Platform for Pain Program Nov 28
Less than half of directors are independent Nov 16
Emyria Limited and The University of Western Australia Expands Unique MDMA Oct 18
Emyria Expands Clinical Sites for EMD-RX5 Phase 3 Trial Sep 26
Emyria Limited, Annual General Meeting, Oct 25, 2022 Aug 31
Full year 2022 earnings released: AU$0.027 loss per share (vs AU$0.022 loss in FY 2021) Aug 30
Emyria Limited Receives Ethics Approval for Pivotal EMD-RX5 Phase 3 Trial Aug 17
Emyria Limited Announces Initiation of Human Cell-Line Preclinical Studies to Advance Its Mdma-Inspired Drug Discovery Partnership with the University of Western Australia Aug 05
Emyria Limited Announces Positive Progress of its Preclinical MDMA Analogue Medicine Program Jul 18
Emyria Limited Reports Positive Phase 1 Trial Data for EMD-RX5 Indicating Ideal Bioavailability, Safety and Tolerability Among 12 Healthy and Demographically Diverse Volunteer Subjects May 26
Emyria Limited Receives Further Positive MDMA Analogue Screening Results May 12
Less than half of directors are independent Apr 27
Emyria Limited Announces EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial Apr 14
Emyria Limited Commences Dosing for EMD-RX5 Phase 1 Human Clinical Trial Apr 07 Emyria Limited Commences for the EMD-RX5 Clinical Development Program Mar 10
Emyria Limited Ethics Approval Receives for EMD-RX5 Phase 1 Study Mar 04
Emyria Limited Announces Substantial Expansion of Proprietary MDMA Analogue Library Being Created with the University of Western Australia Feb 22
Emyria Limited Announces Phase 1 Clinical Trials to Commence for Its Leading Ultra-Pure CBD Drug Candidate, Referred to as EMD-RX5 Jan 20
Emyria Limited announced that it expects to receive AUD 5 million in funding from Tattarang Pty Ltd Nov 22
Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020) Oct 04
Emyria Limited Provides Novel Mdma Analogue Screening Program Advanced Update Sep 24
Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020) Sep 02
Emyria Executes Pure CBD Agreement with Altasciences to Accelerate FDA and TGA Cannabinoid Registration Programs Aug 13
Emyria Advances EMD-004 Program Towards Registration Jun 15
Emyria Limited and Mind Medicine Australia Launch MDMA-Assisted Therapy Program for PTSD May 05
First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.016 loss in 1H 2020) Feb 25
Emyria Limited Announces the Appointment of Dr. Karen Smith to Chair the Company's Strategic Advisory Board Feb 22
New 90-day high: AU$0.23 Feb 15
Emyria Limited Wins Digital Health Monitoring Grant with UWA Feb 05
Emyria Limited Appoints Dr Richard Magtengaard, to Its Medical Advisory Board Feb 01
Emyria Limited to Pursue Registration of EMD-003 with Australia's Therapeutic Goods Administration in 2021 Jan 06
Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million. Dec 23
Emyria Limited Launches Drug Development Program Based on RWE Nov 25
Emyria Limited Partners with Mind Medicine Australia Nov 19
Executive Chairman recently bought AU$61k worth of stock Nov 17
Emyria Limited Enters Data Deal with Zelira to Support Autism Trial Nov 09
Zelira Therapeutics Ltd Enters into Agreement with Emyria Ltd Oct 03
Emerald Clinics Limited to Report Fiscal Year 2020 Results on Oct 30, 2020 Sep 07 Shareholder Returns EMD AU Pharmaceuticals AU Market 7D -10.5% 4.5% 1.4% 1Y -35.8% -8.5% 9.9%
See full shareholder returns
Return vs Market: EMD underperformed the Australian Market which returned 9.6% over the past year.
Price Volatility Is EMD's price volatile compared to industry and market? EMD volatility EMD Average Weekly Movement 13.0% Pharmaceuticals Industry Average Movement 9.6% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.4% 10% least volatile stocks in AU Market 3.0%
Stable Share Price: EMD's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: EMD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company Founded Employees CEO Website 2018 n/a Michael Winlo emyria.com
Emyria Limited engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia. It develops MDMA-inspired medicines, including EMD-MX1, for faster-acting MDMA with improved side-effect profile for drug-assisted therapies; EMD-MX2, an adjunct for Parkinson’s disease to improve side effects of a common treatment; and EMD-MX3 for other neurological indications. The company is also developing EMD-RX7/9, a CBD capsule prescription medicines for complex pain and anxiety which is under preclinical trial program; and provides psychological trauma care facility under the Pax Centre name.
Show more Emyria Limited Fundamentals Summary How do Emyria's earnings and revenue compare to its market cap? EMD fundamental statistics Market cap AU$15.66m Earnings (TTM ) -AU$11.46m Revenue (TTM ) AU$2.20m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) EMD income statement (TTM ) Revenue AU$2.20m Cost of Revenue AU$2.37m Gross Profit -AU$167.55k Other Expenses AU$11.29m Earnings -AU$11.46m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.025 Gross Margin -7.61% Net Profit Margin -520.07% Debt/Equity Ratio 33.5%
How did EMD perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/11 10:44 End of Day Share Price 2025/02/11 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Emyria Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
